TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK “Takeda”) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).

东京和波士顿——（商业新闻短讯）——Alloy Therapeutics Inc.（“Alloy”）是一家致力于使尖端药物发现技术民主化的生物技术生态系统公司，今天宣布与武田制药有限公司（TSE:4502/NYSE:TAK“Takeda”）达成战略合作和许可协议，以开发武田专有的诱导多能干细胞（iPSC）衍生的CAR-T细胞平台（iCAR-T）和iPSC衍生的CAR-NK平台（iCAR-NK）。

Alloy will focus on accelerating the development of key therapies to overcome solid and hematological malignancies..

Alloy 将致力于加速开发攻克实体肿瘤和血液恶性肿瘤的关键疗法。

iCAR-T technology was developed as part of the T-CiRA joint research program between Takeda and the Center for iPS Research and Application (CiRA) at Kyoto University. The core technology to differentiate iPSC into immune cells originates from CiRA’s Shin Kaneko’s laboratory. iCAR-T has potential to develop ‘off-the-shelf’ cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy..

iCAR-T技术是武田和京都大学iPS研究与应用中心（CiRA）之间的T-CiRA联合研究计划的一部分。。iCAR-T有潜力开发“现成”的细胞疗法，与自体细胞疗法相比，具有增强效力的最佳性能潜力，并且制造成本显着降低。。

“iCAR-T is one of our flagship projects graduating from T-CiRA, our decade-long joint research program between Takeda and CiRA. This agreement between Takeda and Alloy aims to advance iCAR-T from discovery to clinical development,” said Yasushi Kajii, Head of R&D Japan Region at Takeda. “We are impressed with Alloy’s corporate culture of valuing platform technologies, flexibility in collaboration, patient-centric mindset, and company creation abilities, all of which were key elements to our decision to work with Alloy.

“iCAR-T是我们从T-CiRA毕业的旗舰项目之一，T-CiRA是武田和CiRA之间长达十年的联合研究项目。武田和Alloy之间的这项协议旨在将iCAR-T从发现推进到临床开发，”武田日本研发区负责人Yasushi Kajii说。“我们对Alloy重视平台技术、协作灵活性、以患者为中心的心态和公司创造能力的企业文化印象深刻，所有这些都是我们决定与Alloy合作的关键因素。

We look forward to seeing iCAR-T and iCAR-NK blossom as the technology advances to its next phase.”.

随着技术发展到下一阶段，我们期待着看到iCAR-T和iCAR-NK开花。”。

Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Alloy will leverage synergies across its unique business model to further advance the iCAR-T/NK platform while enabling broader access to the technology for biotech and pharma partners to develop therapies for cancers including solid tumors.

根据该协议，Alloy获得了用于肿瘤适应症的iCAR-T和iCAR NK产品商业化的共同专有权。Alloy将利用其独特商业模式的协同作用，进一步推进iCAR-T/NK平台，同时使生物技术和制药合作伙伴能够更广泛地获得该技术，以开发包括实体瘤在内的癌症治疗方法。

Future clinical validation and platform enhancements will further strengthen the platform..

未来的临床验证和平台增强将进一步加强平台。。

“We are honored and excited to be chosen by Takeda to collaborate in fulfilling the promise of iPSC,” said Errik Anderson, Founder, Chairman & CEO of Alloy. “This is another instance of how Alloy’s flexible approach allows us to enable the global scientific community with cutting edge technologies designed for rapid, successful drug development.

Alloy创始人、董事长兼首席执行官埃里克·安德森（ErrikAnderson）表示：“我们很荣幸和兴奋能被武田选中，共同履行iPSC的承诺。”。“这是Alloy灵活的方法如何使我们能够为全球科学界提供旨在快速成功开发药物的尖端技术的另一个例子。

We believe a robust engagement with the ecosystem will play a critical role in unlocking the vast potential of iPSC and enabling the next generation of cancer therapeutics.”.

我们相信，积极参与生态系统将在释放iPSC的巨大潜力和实现下一代癌症治疗方面发挥关键作用。”。

To support these efforts, Alloy is establishing a Japanese subsidiary at Shonan Health Innovation Park in Kanagawa Prefecture, to be led by Victor Stone (Yoshihide Ishii) as the Head of Alloy Cell Therapies and Alloy Therapeutics Japan.

为了支持这些努力，Alloy正在神奈川县Shonan Health Innovation Park成立一家日本子公司，由Victor Stone（Yoshihide Ishii）领导，担任Alloy Cell Therapeutics和Alloy Therapeutics Japan的负责人。

About Alloy Therapeutics

关于 Alloy Therapeutics

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities: antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery.

Alloy Therapeutics是一家生物技术生态系统公司，授权全球科学界共同生产更好的药物。通过学术界、生物技术界和最大的生物制药界的合作伙伴社区，Alloy将竞争前工具、技术、服务和公司创建能力的获取民主化，这些能力是发现和开发六种治疗性生物制剂的基础：抗体、TCR、基因药物、肽、细胞疗法和药物输送。

Partners may access all current and future technologies through a discovery service relationship or for a flat fee through Alloy’s Innovation Subscriptions offering. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

合作伙伴可以通过发现服务关系或通过Alloy的创新订阅服务获得所有当前和未来的技术。Alloy将其收入的100%用于创新和获取创新，这反映了Alloy对科学界的不懈承诺。

About Takeda

关于武田

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

武田致力于为人们创造更好的健康，为世界创造更美好的未来。我们的目标是在我们的核心治疗和业务领域发现并提供改变生命的治疗方法，包括胃肠道和炎症、罕见疾病、血浆衍生疗法、肿瘤学、神经科学和疫苗。

Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet.

与我们的合作伙伴一起，我们的目标是通过我们动态多样的渠道改善患者体验，并推进治疗选择的新前沿。作为总部位于日本的领先的基于价值观、研发驱动的生物制药公司，我们以对患者、人民和地球的承诺为指导。

Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com..

我们在大约80个国家和地区的员工是由我们的目标驱动的，并以两个多世纪以来定义我们的价值观为基础。有关更多信息，请访问www.takeda.com。。